GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » 5-Year Yield-on-Cost %

BioLine Rx (BioLine Rx) 5-Year Yield-on-Cost % : 0.00 (As of May. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx 5-Year Yield-on-Cost %?

BioLine Rx's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for BioLine Rx's 5-Year Yield-on-Cost % or its related term are showing as below:



BLRX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of BioLine Rx's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, BioLine Rx's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's 5-Year Yield-on-Cost % falls into.



BioLine Rx 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of BioLine Rx is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

BioLine Rx  (NAS:BLRX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


BioLine Rx 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus